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Abstract
Background: Although brucea javanica oil liposomes (BJOLs) have been used clinically to treat ovarian cancer, its
clinical efficacy is often limited by systemic side effects due to non-specific distribution. Luteinizing hormone
releasing hormone receptor (LHRHR) is overexpressed in most ovarian cancers but negligibly expressed in most of
the other visceral organs. In this study, we aimed to develop a novel LHRHa targeted and BJO-loaded liposomes
(LHRHa-BJOLs), and investigate its characteristics, targeting ability and anti-ovarian cancer efficiency both in vitro
and in vivo.
Methods: The LHRHa-BJOLs were prepared by film-dispersion and biotin-streptavidin linkage methods, and
characterized in terms of its morphology, particle size, zeta potential, ligand conjugation, encapsulation efficiency
and stability. The targeting nature and antitumor effects of the liposomes were evaluated in vitro using cultured
human ovarian cancer A2780/DDP cells, and in vivo using ovarian cancer-bearing nude mice.
Results: The LHRHa-BJOLs were successfully synthesized, with a uniformly spherical shape, appropriate particle size
and zeta potential, as well as a high encapsulation efficiency. Compared to non-targeted liposomes and BJO
emulsion, the LHRHa-BJOLs could significantly increase specific intracellular uptaking rate, enhance cell inhibitory
effect and induce cell apoptosis in A2780/DDP cells in vitro. Meanwhile, LHRHa-BJOLs also had a significantly
stronger activity of targeting tumor tissue, inhibiting tumor growth, inducing tumor apoptosis and prolonging
survival time in ovarian cancer-bearing mice in vivo.
Conclusions: Our experiment suggests that LHRHa-BJOLs may be a useful targeted drug for the treatment of
ovarian cancer.
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Background
Ovarian cancer is the leading cause of death from gyneco-
logic malignancy [1–3], and is a silent killer with stable in-
cidence and poor prognosis due to the difficulties of early
diagnosis [4]. The treatment of ovarian cancer usually in-
volves debulking surgery and chemotherapy [5, 6]. Seed
oil of Brucea javanica (BJO), a traditional herbal medicine,
is extracted from the seeds of Brucea javanica [7], and has
been used clinically to treat various tumors, including
ovarian cancer [7–9]. The mechanisms of antitumor activ-
ity of BJO include inducing tumor apoptosis and reversing
multidrug resistance [10, 11]. However, its clinical use is
limited due to non-specific distribution, low therapeutic
index and systemic side effects [8].
Considerable research has been carried out to overcome
these defects, including develop improved dosage and
drug delivery systems. Liposomes have been developed as
an effective drug carrier due to their ability to deliver en-
capsulated drugs to specific target sites, provide sustained
drug release and protect encapsulated agents [12–14].
Furthermore, many targeting ligand-conjugated liposomes
have been tested in recent years, including natural or syn-
thetic ligands. Luteinizing hormone releasing hormone
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receptor (LHRHR) is overexpressed in approximately 70–
80 % of ovarian cancer cells, however, its expression in
most of the other visceral organs is negligible [15–17].
Since natural LHRH is unstable in vivo, LHRH analogue
(LHRHa) with improved bioactivity has been synthesized
as an ovarian cancer seeking agent to target LHRHR [18].
Previous animal studies have shown that an LHRHa
targeted drug delivery system exhibits no pituitary toxicity,
insignificant influence on the luteinizing hormone con-
centration, and negligible effect on the reproductive func-
tions [17]. In addition, LHRHa is a stable protein with
well-defined reaction sites for conjugation, and has been
shown to undergo receptor-mediated endocytosis, and
transporting the ligand-receptor complex into the cells
[18, 19]. More recently, we have successfully synthesized
an LHRHa conjugated and paclitaxel loaded microbubbles
for ultrasound mediated chemotherapy that induced
ovarian cancer apoptosis in vitro and in vivo [20–23].
In this study, we coupled the LHRHa ligands with BJO-
loaded liposomes (LHRHa-BJOLs) to target human ovar-
ian cancer A2780/DDP cells that express the LHRHR. The
BJO loading rate in liposomes was detected by an ultravio-
let spectrophotometry, and the LHRHa in BJO loaded li-
posomes (BJOLs) was detected by immune colloidal gold
technique and observed by transmission electron micros-
copy. The targeted uptaking of LHRHa-BJOLs to cancer
cells was observed by fluorescence microscope and ana-
lyzed by flow cytometry. The anticancer effects of
LHRHa-BJOLs were then tested in vitro and in vivo. Our
experiment verifies the hypothesis that LHRHa-BJOLs will
enhance the efficacy of BJO therapy. To the authors’
knowledge, no similar study has been reported elsewhere.
Methods
Cell lines and culture
Human ovarian cancer A2780/DDP cells (LHRHR positive
[20]) were kindly provided by Professor Zehua Wang from
Wuhan Union Hospital (Wuhan, China). SKOV3 cells
(LHRHR negative [22]) were obtained from School of Life
and Health Sciences, Chongqing Medical University
(Chongqing, China). The cells were grown in RPMI-1640
medium (HyClone, Utah, USA) at 37 °C under a humidi-
fied atmosphere of 5 % CO2, and supplemented with 10 %
fetal bovine serum (Tianhang Biotechnology Co., Ltd.,
China) and 1 % penicillin-streptomycin.
Animal model preparation
Female BALB/c-nu/nu nude mice (4–5 weeks old; body
weight, 18–20 g) were purchased from the Animal
Centre of Chongqing Medical University and housed in
laminar flow rooms under constant temperature (22 ±
2 °C), humidity and specific pathogen-free conditions.
Tumors were established by subcutaneous injection of
A2780/DDP cells. A2780/DDP cells were suspended in
serum-free RPMI-1640 medium to reach a cell density
of 4 × 107/ml and injected subcutaneously into the left
flanks of the mice at a dose of 0.2 ml, tumors were
inspected by observation and palpation. All animal experi-
ments were approved ethically and scientifically by the
Chongqing Medical University in accordance with the
Practice Guidelines for Laboratory Animals of China.
Preparation of LHRHa-BJOLs
LHRHa-BJOLs were prepared by the film-dispersion and
biotin-streptavidin linkage methods. Briefly, the mixtures of
Soybean phosphatidylcholine (Lipoid Co., Ltd., Germany),
Cholesterol (Sigma Aldrich Co., Ltd., St. Louis, USA), 1,2-
distearoyl-sn-glycero-3-phosphoethanol-amine-N-[biotinyl
(polyethyleneglycol) (2000)] (DSPE-PEG2000-Biotin, Avanti
Polar Lipids Co., Ltd., Alabaster, USA) and BJO (Yaoda
Pharmaceutical Co., Ltd., Shenyang, China) (194:50:6:75, w/
w) were fully dissolved in sufficient chloroform and metha-
nol (5:1, v/v) in a round bottom flask. The organic solvent
was removed by rotary evaporation (37 °C, 100 r/min,
5Kpa, 30 to 40 min) and the resulting film was dried by
storing in a vacuum overnight. After hydrating the film in
3 ml phosphate buffered saline (PBS, PH 7.4, 290 mosm,
Zhongshanjinqiao Biotechnology Co., Ltd., Beijing, China),
the solution was sonicated for 8 min at 4 °C in an ultra-
sonic water bath. The suspensions were then filtered by
0.45 μm and 0.22 μm microfiltration membrane in se-
quence, and the BJOLs were obtained. Streptavidin (SA,
SA: DSPE-PEG2000-Biotin = 1:8, molar ratio) was added to
the BJOLs solution and incubated at 4 °C with gentle stir-
ring for 30 min. An excessive amount of the biotinylated
LHRHa (Beijing Zhongkeyaguang Biotechnology Co., Ltd.,
Beijing, China) was then added into the solution and gentle
stirred at 4 °C for another 30 min to form the LHRHa-
BJOLs. Finally, Sephadex G-50 column (Pharmacia Biotech
Inc., New Jersey, USA) was used to separate LHRHa-BJOLs
from the free streptavidin and LHRHa peptide. Coumarin-
6 loaded liposomes (C6Ls) and LHRHa-modified C6Ls
(LHRHa-C6Ls), being used as fluorescently labelled probes,
were prepared as described above by substituting the BJO
with coumarin-6 (Sigma Aldrich Co., Ltd., St. Louis, USA).
Characterization of LHRHa-BJOLs
The particle size and zeta potential were determined using
dynamic light scattering with the Zetasizer Nano ZS90
(Malvern Instrument Ltd., Worcestershire, UK), samples
were diluted appropriately with double distilled water for
the measurements. The content of BJO in liposomes was
measured by ultraviolet spectrophotometry. LHRHa-
BJOLs suspensions (1 ml) were eluted by PBS in Sephadex
G-50 column, and then the opalescence part of the eluate
was collected. The amount of BJO in the suspensions be-
fore and after passing over the Sephadex G-50 column
(Wtotal and Wfree) were measured. The encapsulation
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efficiency (EE) of BJO in liposomes was calculated with
the formula: EE = (Wtotal - Wfree)/Wtotal × 100 %.
Stability of LHRHa-BJOLs
LHRHa-BJOLs were stored at 4 and 25 °C in the dark for
3, 6, 9, 12, 15 and 30 days, respectively. The percolation
rate (PR) of BJO in different storage conditions was calcu-
lated by the following equation: PR = (EE0 - EE)/EE0 ×
100 %, where the EE0 and EE were the encapsulation effi-
ciency of BJO before and after storage, respectively.
Measurement of LHRHa on the surface of LHRHa-BJOLs
The LHRHa on the BJOLs’ surface was detected by
immune colloidal gold technique and observed by trans-
mission electron microscopy (TEM, H-7500, JEOL,
Japan). Briefly, the rabbit anti-human LHRH monoclonal
antibody (Chemicon International, Inc., USA) was mixed
with the LHRHa-BJOLs and BJOLs, respectively, followed
by an incubation at 4 °C for overnight. After passed over
the Sephadex G-50 column, the suspensions were incu-
bated with goat anti-rabbit IgG labeled with 15 nm immu-
nogold nanoparticles (Bioss Biotechnology Co., Ltd.,
Beijing, China) at room temperature for 90 min, and then
washed with PBS on a Sephadex G-50 column and spread
over a carbon-coated copper grid, negatively stained with
1 % phosphotungstic acid and allowed to dry. The morph-
ology of the LHRHa-BJOLs was then observed using TEM.
In vitro study of the targeted binding affinity
The intracellular uptake of the LHRHa-Liposomes
(LHRHa-Lip) was observed by laser scanning confocal
microscope (LSCM, Leica, Heidelberg, Germany) and
coumarin-6 was used as the fluorescent probe. Briefly,
A2780/DDP and SKOV3 cells were seeded in 6-well plate
in triplicate at a density of 4 × 105/well and incubated for
24 h, respectively. The medium was then changed with
fresh culture medium containing either LHRHa-C6Ls or
C6Ls at a coumarin-6 concentration of 2 μg/ml. After in-
cubated for 1.5 h at 37 °C and washed three times with
pre-cooling PBS to remove unbound liposomes, the cells
were fixed in 4 % paraformaldehyde at 4 °C for 15 min
and washed with PBS. After that, the cells were stained
with DAPI-containing reagent for 5 min and washed with
PBS to remove the free DAPI. The uptaking of LHRHa-
C6Ls or C6Ls in the cancer cells were observed by LSCM.
The intracellular uptake of LHRHa-Lip was also quan-
titatively analyzed by flow cytometry (FCM, FACS, BD
Biosciences, San Jose, CA, USA). Briefly, A2780/DDP
and SKOV3 cells were seeded in 6-well plate in triplicate
at a density of 4 × 105/well and incubated. When 80 %
confluence was reached, the cells were washed with PBS,
and the LHRHa-C6Ls or C6Ls (containing 2ug/ml
coumarin-6) was added, respectively. After 1.5 h incuba-
tion, the cells were washed three times with PBS,
harvested with trypsin, centrifuged, and resuspended at
a concentration of 1 × 106/ml in culture medium. The
mean fluorescent intensity (MFI) of the cells were ana-
lyzed by FCM.
In vitro evaluation of antitumor efficiency
A2780/DDP cells were seeded in 6-well plate (5 × 105
cells/well) in triplicate and incubated for 24 h to allow
cell adhesion. After that, the cells were equally divided
into the following four treatment groups: PBS, BJOE,
BJOLs and LHRHa-BJOLs groups. For BJOE, BJOLs and
LHRHa-BJOLs groups, BJO was administered at a dose
of 0.4 mg/ml.
Cell viability assay
After different treatments, the cells were incubated for a
further 24, 48 and 72 h and washed in PBS for three
times. The number of viable cells in each treatment
group relative to PBS group was evaluated using a 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium brom-
ide (MTT) assay (Sigma Aldrich Co., Ltd., St. Louis,
USA). Briefly, at these designated time points, 20 μl
MTT (5.0 mg/ml) was added and the cells were incu-
bated for another 4 h. Then, the medium was removed,
150 μl dimethylsulfoxide was added and mixed on a
vortex mixer for 10 min. Absorbance (A) at 490 nm was
recorded using the microplate reader (BIO-RADModle
550, Bio-Rad Ltd., USA). The cell inhibitory rate (IR)
was calculated by the following equation: IR (%) = [1 -
(Atreated/Acontrol)] × 100 %.
Apoptosis assay
Twenty-four hours after different treatments, the cell
apoptosis was assessed using an Annexin V-FITC/PI
apoptosis detection kit (Beyotime Biotechnology Co.,
Ltd., Jiangsu, China) as described by the manufacturer’s
instructions. Briefly, A2780/DDP cells treated with various
treatments were harvested with trypsin, washed twice with
PBS, resuspended in Annexin-V binding buffer and incu-
bated in the dark for 15 min with 5 μl AnnexinV-FITC
and 10 μl PI. The apoptosis was evaluated by FCM, and
the apoptosis rate of each group was calculated using Cell
Quest software.
JC-1 mitochondrial membrane potential (MMP) assay
Twenty-four hours after different treatments, the cell
MMP (Δψm) was assessed using a JC-1 MMP assay kit
(Beyotime Biotechnology Co., Ltd., Jiangsu, China) ac-
cording to the manufacturer's instructions. Briefly,
A2780/DDP cells treated with various treatments were
collected and washed with PBS, and incubated with
0.5 ml JC-1 dye in the dark for 20 min at 37 °C. The
cells were then washed twice with JC-1 buffer and then
analyzed by FCM.
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Detection of apoptosis by Hoechst 33258 fluorescent
staining
Twenty-four hours after different treatments, A2780/DDP
cells were washed with PBS, fixed with paraformaldehyde
(Sigma, St. Louis, MO, USA) at room temperature for
15 min and washed with PBS, then stained in Hoechst
33258 dye (4 g/ml, Beyotime Institute of Biotechnology,
China) in dark for 5 min at 37 °C. After been washed with
PBS for three times, the cells were observed under fluores-
cence microscopy. Apoptotic cells were defined with the
changes of nuclear morphology. Normal nuclei showed
diffusely and homogeneously low-intensity fluorescent,
apoptotic nuclei were hyperchromatic and compact at
condensed or granular state.
Bcl-2, Bax and caspase-3 activity
In order to further understand the apoptosis-inducing ef-
fect of LHRHa-BJOLs in ovarian tumor cells, apoptosis-
related proteins, including bcl-2, bax and caspase 3, were
evaluated in A2780/DDP cells at 24 h after different treat-
ments by western blot analysis. The cells in each group
were lyzed in a lysis buffer (50 mM Tris–Cl, pH 7.4,
1 mM EDTA, 150 mM NaCl, 1 % NP40, 0.25 % Na-
deoxycholate, and 1 μg/ml of aprotinin, leupeptin and
pepstatin). Equal amounts of protein (30 μg/sample) were
separated electrophoretically by 15 % SDS-PAGE and
blotted onto a polyvinylidene difluoride membrane, which
was then blocked with PBS containing 5 % non-fat dried
milk for at least 1 h. The blots were incubated at 4 °C
overnight with a primary antibody against bcl-2 (Rabbit
anti-human bcl-2 antibody, CST, Inc., USA), bax (Rabbit
anti-human bax antibody, EPI, Inc., USA) and caspase 3
(Rabbit anti-human caspase-3, Santa, Inc., USA) respect-
ively and followed by incubation with a horseradish
peroxidase-conjugated secondary antibody for 30 min in a
blocking buffer at room temperature. After further wash-
ing, the blots were revealed by enhanced chemilumines-
cence (Pierce ECL detection kit) and exposed to X-ray
film (Eastman-Kodak, Rochester, NY, USA). Equal loading
was confirmed by β-actin detection. Band optical density
(OD) was analyzed using a Labworks 4.6 UVP-image cap-
ture and analysis software package. The analysis results
were expressed in the format of mean ± standard deviation
(SD) as the ratio percentage of the protein of interest OD
versus the β-actin OD.
In vivo evaluation of antitumor efficiency
The anticancer effect of LHRHa-Lip was demonstrated
in an ovarian cancer xenografts model which were estab-
lished as described above. Thirty-two ovarian cancer-
bearing mice were randomly divided into the following
four treatment groups (seven mice per group): PBS (con-
trol), BJOE, BJOLs and LHRHa-BJOLs groups. For each
treatment groups, an equivalent BJO dose of 180 mg/kg
was injected into the mouse caudal veins on days 15, 18,
21, 24 and 27 after tumor inoculation, respectively.
Tumor diameter was measured by a dial caliper once a
week until the 42th day after tumor inoculation. The
subcutaneous tumor volume was estimated by the
following formula: V (mm3) = (length × width2)/2 [24].
Three mice in each group were sacrificed 24 h after the
last treatment and the tumor tissues were harvested for
further protein analysis. The rest of the mice (five in
each group) were monitored daily for the signs of the
reduced physical activity and the progression of the
tumor. The survive time of each mouse was recorded.
Detection of Bcl-2, Bax and caspase-3 expression after in
vivo treatment
The bcl-2, bax and caspase 3 protein expression of the
tumor were characterized by western blot analysis.
Briefly, samples in each treatment group were homoge-
nized and centrifuged at 12000 g for 30 min. The super-
natant was collected and the protein concentration of
the lysate was determined by a Bradford protein assay
(Bio-Rad, Hercules, CA, USA). For western blot analysis,
equal amounts of protein were loaded for SDS-PAGE.
The protein was then transferred to a nitrocellulose
membrane, blocked with PBST (PBS with 0.1 % Tween-20)
solution containing 5 % non-fat milk, and incubated over-
night at 4 °C with a primary antibody against bcl-2, bax
and caspase 3 (polyclonal, 1:1000, Abcam, UK),respectively.
The antibody was detected by a horseradish peroxidase-
conjugated secondary antibody (1:5000) after 1-hour incu-
bation and developed with an ECL detection kit. Equal
loading was confirmed by β-actin detection. Band optical
density (OD) was analyzed using a Labworks 4.6 UVP-
image capture and analysis software package. The analysis
results were expressed in the format of mean ± standard
deviation (SD) as the ratio percentage of the protein of
interest OD versus the β-actin OD.
Statistical analysis
Data were analyzed using the Statistical Package for
Social Sciences (SPSS) software for Windows, version
22.0 (SPSS Inc., Chicago, USA). One-way analysis of vari-
ance (ANOVA) for multiple-group analysis, unpaired stu-
dent’s t-test was used for between two-group comparison,
and log-rank test was used for the data of lifetime com-
parison. The data were expressed as mean value ± stand-
ard deviation x  sð Þ , a p value of less than 0.05 was
considered statistically significant.
Results
Characterization of the LHRHa-BJOLs
TEM image showed that the LHRHa-BJOLs were gener-
ally spherical in shape, and there were obvious black
spots (immunogold nanoparticles labeled LHRHa) on
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the surface of LHRHa-BJOLs, while no black spots on the
surface of BJOLs (Fig. 1), indicating that LHRHa peptide
was indeed conjugated on the surface of the LHRHa-
BJOLs [25]. The mean size of LHRHa-BJOLs was (155.1 ±
14.5) nm, and the polydispersity index (PDI) was 0.227,
indicating a narrow size distribution. The mean zeta
potential of LHRHa-BJOLs was - (24.1 ± 0.54) mV. The
encapsulation efficiencies (EE) of LHRHa-BJOLs and
BJOLs were (92.2 ± 1.59) % and (93.6 ± 1.04) %, respect-
ively. No significant difference in encapsulation efficien-
cies was observed between LHRHa-BJOLs and BJOLs,
indicating that the modification of the liposomes with the
LHRHa peptide had no significant influence on the encap-
sulation efficiencies of the liposomes. After storing in 4 °C
in the dark for 3, 6, 9, 12, 15 and 30 days, the percolation
rates of LHRHa-BJOLs were 0.12, 0.18, 0.23, 0.67, 1.14
and 1.26 %, respectively. In comparison, when the
LHRHa-BJOLs were storied in 25 °C for the same time,
the percolation rates were 4.36, 9.52 12.84 15.67 19.25 and
20.08 %, respectively. This indicates that LHRHa-BJOLs
were more stable when stored in 4 than 25 °C and it could
be stored at 4 °C more than 30 days.
Intracellular uptake of LHRHa-Lip in vitro
Figure 2a shows the fluorescence microscopic images
acquired for A2780/DDP and SKOV3 cells treated with
LHRHa-C6Ls and C6Ls, respectively. A2780/DDP cells
treated with LHRHa-C6Ls exhibited higher fluorescence
emission than it treated with C6Ls, indicating that
LHRHa-C6Ls yields the higher liposome uptaking in
LHRHR positive A2780/DDP cells. In comparison,
SKOV3 cells treated with LHRHa-C6Ls or C6Ls exhib-
ited the same fluorescence emission, indicating that
LHRHa-C6Ls doesn’t yield the higher liposome uptaking
in LHRHR negative SKOV3 cells. Quantitative analysis
of the fluorescence emission intensities by FCM analysis
for these treatment groups also yielded consistent con-
clusions. According to Fig. 2b and c, the fluorescence
intensity for A2780/DDP cells treated with LHRHa-C6Ls
or C6Ls were (211.09 ± 8.96), and (101.93 ± 1.50), re-
spectively. Whereas those for SKOV3 cells were (111.76
± 23.22) and (107.04 ± 13.83), respectively. Compared
with other treatment groups, A2780/DDP cells treated
with LHRHa-C6Ls had the highest liposomes uptaking
efficiency and the differences were statistically significant
(p < 0.05). These experimental results indicate that the
increased delivery of LHRHa-C6Ls to A2780/DDP cells
is LHRHa mediated.
Cell viability after LHRHa-BJOLs treatment in vitro
The cytotoxicity profiles of different treatment options
(BJOE, BJOLs and LHRHa-BJOLs) was evaluated by a
MTT assay and compared with the control treatment
(PBS). Figure 3 compares the cell proliferation inhibitory
rates at 24, 48 and 72 h after different treatments. Ac-
cording to the figure, the cell proliferation inhibitory
rates were less than 30 % for BJOE group. In compari-
son, BJOLs yielded the cell proliferation inhibitory rates
of (21.63 ± 2.19) %, (31.86 ± 2.17) % and (49.12 ± 3.61) %,
while LHRHa-BJOLs yielded the cell proliferation inhibi-
tory rates of (37.66 ± 1.73) %, (51.26 ± 3.46) % and
(65.45 ± 4.42) % at 24, 48 and 72 h after treatment, re-
spectively. Obviously, LHRHa-BJOLs group resulted in
significantly stronger inhibitory effects on the prolifera-
tion of A2780/DDP cells. Furthermore, BJOE, BJOLs
and LHRHa-BJOLs were found to inhibit A2780/DDP
cells in a time-dependent manner.
Inducing apoptosis in a flow cytometer assay, Hoechst
33258 fluorescent staining and western blotting analysis
FCM analysis was used to evaluate the percentages of
apoptotic cells following each treatment (Fig. 4a). The
results demonstrated that BJOE, BJOLs and LHRHa-
BJOLs induced significantly more apoptosis of A2780/
DDP cells than PBS. The highest apoptosis rate was ob-
served in LHRHa-BJOLs group, with (33.36 ± 1.31) %
Fig. 1 Transmission electron microscopy image of BJO-loaded liposomes. There were obvious black spots (immunogold nanoparticles labeled
LHRHa, black arrow) on the surface of the LHRHa modified BJO-loaded liposomes, while no black spots on the surface of the BJO-loaded liposomes
without LHRHa modification
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Fig. 2 Intracellular uptake of LHRHa-liposomes in vitro. a Fluorescence microscopic images acquired for A2780/DDP and SKOV3 cells treated with
LHRHa-C6Ls and C6Ls, respectively. A2780/DDP cells treated with LHRHa-C6Ls exhibited higher fluorescence emission than it treated with C6Ls. In
comparison, SKOV3 cells treated with LHRHa-C6Ls or C6Ls exhibited the same fluorescence emission. b and c, Mean fluorescence intensity (MFI)
of A2780/DDP and SKOV3 cells by flow cytometry analysis. A2780/DDP cells plus LHRHa-C6Ls group had the highest liposomes uptaking efficiency
when compared with other groups (p < 0.05). Compared with LHRHa-C6Ls group, *p < 0.05; compared with A2780/DDP cells, #p < 0.05
Fig. 3 Growth inhibitory effects of different treatments on the proliferation of A2780/DDP cells determined by MTT. The proliferation inhibitory
rate of LHRHa-BJOLs group is significantly higher than those of other group (p < 0.05). Furthermore, BJOE, BJOLs and LHRHa-BJOLs were found to
inhibit A2780/DDP cells in a time-dependent manner. Compared with LHRHa-BJOLs group, *p < 0.05; compared with the same group at 72 h after
treatment, #p < 0.05
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after 24 h incubation, and was significantly higher than
in BJOLs (22.34 ± 2.88) %, BJOE (12.15 ± 2.93) % and
control groups (6.95 ± 2.29) % (p < 0.05), indicating the
significant increase of the cell apoptosis efficiency by
LHRHa-BJOLs treatment. Quantitative analysis of the
mitochondrial membrane potential (MMP) decrease by
FCM analysis for these treatment groups also yielded
consistent conclusions. According to Fig. 4b, the MMP
decrease rate in PBS, BJOE, BJOLs and LHRHa-BJOLs
groups were (4.70 ± 2.11 %) %, (17.59 ± 4.15) %, (25.69 ±
2.95) % and (38.16 ± 5.08) %, respectively. Compared
with other treatment groups, LHRHa-BJOLs group ex-
hibited the highest MMP decrease rate (p < 0.05).
Cell apoptosis was also detected by Hoechst 33258
fluorescent staining. Figure 4c shows the fluorescence
microscopic images acquired for the four groups. PBS
group exhibited normal nuclear morphology, nuclei fluo-
resced faint blue and the color was homogenous. BJOE
group also exhibited faint blue fluorescence emission,
only a few chromatin condensation were observed, indi-
cating that application of BJOE can induce A2780/DDP
cell apoptosis slightly. BJOLs group exhibited moderate
blue fluorescence emission and some nuclear condensa-
tion and morphological changes such as chromatin con-
densation and fragmentation were observed, indicating
that BJOLs may enhance cell apoptosis even without the
use of a targeting vector. LHRHa-BJOLs group exhibited
the highest blue fluorescence emission and chromatin
condensation and fragmentation could be visualized in
many cells, indicating that LHRHa modification of the
BJOLs yields the highest apoptosis efficiency.
Tumor apoptosis related protein bcl-2, bax and cas-
pase 3 expression after different treatment was evaluated
by western blot assay. As shown in Fig. 4d, cells treated
with LHRHa-BJOLs showed more prominent bands of
bax and caspase 3 and less band of bcl-2 than other
Fig. 4 Apoptosis efficiency in A2780/DDP cells in different treatment group. a The percentage of apoptosis cells was determined by flow cytometry
(FCM) 24 h after treatment. The cell apoptosis rate was higher in all the treatment groups in compared with control group (p < 0.05), the highest
apoptosis rate was observed in LHRHa-BJOLs group (p < 0.05). b Mitochondrial membrane potential (MMP) decrease rate detected by FCM. The cell
MMP was lower in all the treatment groups in compared with control group (p < 0.05), LHRHa-BJOLs group had the lowest MMP in compared with
other treatment groups (p < 0.05). c Cell apoptosis detected by Hoechst 33258 fluorescent staining. PBS group exhibited normal nuclear morphology,
nuclei fluoresced faint blue and the color was homogenous. BJOE group also exhibited faint blue fluorescence emission, only a few chromatin
condensation were observed. BJOLs group exhibited moderate blue fluorescence emission and some nuclear condensation and morphological changes
such as chromatin condensation and fragmentation. LHRHa-BJOLs group exhibited the highest blue fluorescence emission, chromatin condensation and
fragmentation could be visualized in many cells, indicating that LHRHa modification of the BJOLs yields the highest apoptosis efficiency. Compared with
LHRHa-BJOLs group *p< 0.05; compared with control group, #p < 0.05. d Western blot analysis of the expression bcl-2, bax and caspase 3 protein in
A2780/DDP cells after different treatments, LHRHa-BJOLs group showed more prominent bands of bax and caspase 3 and less band of bcl-2 than other
treatment groups. e The expression levels of bcl-2, bax and caspase 3 protein in different treatments groups. LHRHa-BJOLs group manifested the highest
expression of bax and caspase-3 and the lowest expression of bcl-2, and the differences were statistically significant. Compared with control group,
*p < 0.05; compared with LHRHa-BJOLs group, #p < 0.05
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treatment groups. Figure 4e shows the expression levels
of bcl-2, bax and caspase-3 respectively for four treatment
groups. The indexes of bcl-2/β-action for PBS, BJOE,
BJOLs and LHRHa-BJOLs groups were (1.07 ± 0.04),
(0.76 ± 0.05), (0.43 ± 0.05), and (0.16 ± 0.03), respectively.
Whereas the indexes of bax/β-action were (0.32 ± 0.11),
(0.96 ± 0.23), (1.56 ± 0.19) and (2.32 ± 0.11), and the in-
dexes of caspase 3/β-action were (0.22 ± 0.02), (0.51 ±
0.02), (0.80 ± 0.03) and (1.07 ± 0.03), respectively. Com-
pared with control group, the expression levels of bax and
caspase 3 were upregulated and bcl-2 was downregulated
in BJOE, BJOLs and LHRHa-BJOLs groups. Compared
with other treatment groups, LHRHa-BJOLs group exhib-
ited the highest expression of bax and caspase-3 and the
lowest expression of bcl-2, and the differences were statis-
tically significant (p < 0.05).
Establishment of ovarian cancer-bearing mice
The ovarian cancer-bearing mice were successfully
established by subcutaneously injection of A2780/DDP
cells in nude mice. The mice were in good condition in
the early days after inoculation, but the mobility and eat-
ing habits began to decline from about 3 weeks after in-
oculation, especially in control and BJOE groups. During
the period of treatment, one mouse in BJOE group ex-
hibited diarrhea and reduced activity at 14 days after
tumor inoculation (one day before the first treatment)
and recuperated within the next 2 days; while one mouse
in BJOLs group showed diarrhea and decreased appetite
at 22 days after tumor inoculation (1 day after the third
treatment) and returned to the average level in the next
day. By the end of the experiment, all the animals
died of the progressive tumor growth with no obvious
evidence of toxicity.
Measurement of tumor volume after in vivo treatment
The tumor nodules were palpable 7 days and visible
14 days after inoculation, photographic images were also
taken after each treatment session (Fig. 5a), the LHRHa-
BJOLs group exhibited the lowest level of tumor volume,
and this was further verified by calculating the relative
tumor volumes of different treatment groups at different
time. Figure 5b plots the tumor growth curve for the
different treatment groups, according to the figure, the
tumors’ volume in the experiment groups were signifi-
cantly smaller compared to that in the PBS control group
(p < 0.05), and the mice in the treatment group of
LHRHa-BJOLs manifested the slowest tumor growth rate.
Expression of Bcl-2, Bax and caspase 3 in tumor tissue
Tumor apoptosis related proteins, bcl-2, bax and caspase
3, were evaluated by western blot analysis. Figure 5c and
d shows the expression levels of bcl-2, bax and caspase 3
after different treatment groups. The indexes of bcl-2/β-
action for PBS, BJOE, BJOLs and LHRHa-BJOLs groups
were (1.16 ± 0.01), (0.95 ± 0.02), (0.62 ± 0.01) and (0.37 ±
0.001), respectively. Whereas the indexes of bax/β-action
were (0.06 ± 0.001), (0.26 ± 0.001), (0.67 ± 0.01) and
(1.08 ± 0.01), and the indexes of caspase 3/β-action were
(0.38 ± 0.001), (0.71 ± 0.01), (1.03 ± 0.01) and (1.12 ±
0.01), respectively. Compared with the other treatment
groups, LHRHa-BJOLs group has the highest expression
of bax and caspase-3 and the lowest expression of bcl-2,
and the differences were statistically significant (p <
0.05). These results indicate that LHRHa-BJOLs signifi-
cantly upregulated pro-apoptotic protein bax and down-
regulated anti-apoptotic protein bcl-2 expression, and
increase apoptosis related protein caspase 3 expression,
which were consistent with the in vitro results.
Survival analysis after in vivo treatment
By the end of the experiment, all the mice died of the
progressive tumor growth. Figure 6 plots the survival
curves, the control group had a median survival time of
42.40 ± 1.47 days, while the other three treatment groups
exhibited different levels of the extended survival time,
46.00 ± 1.18 days in BJOE group, 52.00 ± 1.40 days in
BJOLs group and 58.60 ± 1.03 days in LHRHa-BJOLs
group. The BJOLs and LHRHa-BJOLs groups showed a
superior therapeutic outcome with the median survival
time significantly longer than other two groups, and the
LHRHa-BJOLs group exhibited the longest survival time
which was also significantly longer than BJOLs group.
Additionally, compared with control group, BJOE also
yielded the increased survival time to some extent, but
the difference was not significant, implying that direct
application of BJOE intravenously without liposomes
mediation cannot prolong the survival time significantly,
although it can induce significantly more tumor cells
apoptosis related protein expression as described above.
Discussion
Brucea javanica oil (BJO) is a complex mixture of fatty
acids and its derivatives. It’s main component are oleic
acid and linoleic acid [9], and has been used to treat
various tumors for many years in China [26–29]. How-
ever, its non-specific distribution and low therapeutic
index are two main reasons for poor prognosis in tumor
therapy. Liposomes is regarded as a promising drug car-
rier with good biocompatibility, biodegradability and low
cytotoxicity for cancer therapeutics [30], and it is also
beneficial for the parenteral delivery of insoluble drugs
because it’s better stability in plasma [12, 13]. LHRHa
peptide has been used to target the corresponding LHRHR
over-expressed in the plasma membrane of ovarian cancer
[15, 16, 31]. and we also have successfully coated micro-
bubbles (MBs) with LHRHa to enhance the binding affin-
ity with ovarian cancer cells [20–22]. Therefore, we
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hypothesize that new LHRHa-targeted and BJO-loaded li-
posomes (LHRHa-BJOLs) will facilitate drug deposition at
the tumor site for the enhanced therapeutic outcome. The
results obtained in this in vitro and in vivo study are posi-
tive and in agreement with our study design, rendering the
proposed LHRHa-BJOLs is a promising and novel target-
ing therapy strategy for the treatment of ovarian cancer.
In the present study, LHRHa-BJOLs have been suc-
cessfully developed, and the colloidal gold immunoassay
test had verified that LHRHa peptide was indeed conju-
gated on the surface of the liposomes. Particle size, zeta
potential and encapsulation efficiency are the properties
that influence the biopharmaceutical characteristics and
stability of a liposomes. The smaller liposomes can more
easily evade the reticuloendothelial system (RES) and
prolong the time in circulation [7, 32, 33]. It has been
reported that particle size of the drug carrier should be
bigger than 10 nm to escape the first-pass elimination by
the kidney [34–36], while with particle size less than
200 nm could increase drug accumulation in the tumor
via “enhanced permeability and retention (EPR)” effect
[25, 37–40]. Meanwhile, the particle size also makes an
effect on their interactions with the target cells [40].
Therefore, the LHRHa-BJOLs synthesized in this study
had an optimal size (155.1 ± 14.5 nm) for the tumor tar-
geting by the EPR effect. The zeta-potential is a widely
accepted parameter to represent the surface charge of
the liposomes, and could influence on both its colloidal
stability in suspension and its interaction with cells [41].
For LHRHa-BJOLs synthesized in this study, the zeta
potentials was - (24.1 ± 0.54) mV, demonstrating that the
negatively charged DSPE-PEG2000 was successfully inserted
into the outer monolayer of the vesicles [40]. Furthermore,
the zeta potential was within the range from −20 mV to
Fig. 5 Growth inhibition of A2780/DDP derived tumors in the tumor xenograft models. a Typical photographs of mice bearing A2780/DDP tumors
after the different treatment. Representative photographs from each group. b The tumor growth curve for the different treatment groups (n = 5 in
each group). The tumors’ volume in the experiment groups were significantly smaller compared to that in the PBS control group (p < 0.05), and the
mice in the treatment group of LHRHa-BJOLs manifested the slowest tumor growth rate. c Western blot analysis of the expression bcl-2, bax and
caspase 3 protein in tumor tissue after different treatments, LHRHa-BJOLs group showed more prominent bands of bax and caspase 3 and less band
of bcl-2 than other treatment groups (n = 3 in each group). d The expression levels of bcl-2, bax and caspase 3 protein in different treatments groups.
LHRHa-BJOLs group has the highest expression of bax and caspase-3 and the lowest expression of bcl-2, and the differences were statistically
significant (n = 3 in each group). Compared with control group, *p < 0.05; Compared with LHRHa-BJOLs group, #p < 0.05
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−30 mV, considering to be stable in aqueous environment
without flocculation [42]. Additionally, the encapsulation
efficiency was (93.6 ± 1.04) % before conjugation, and de-
clined to (92.2 ± 1.59) % after conjugation, similar to that
reported by Cui et al. [10]. The slight drug loss might be
due to the release of BJO from the liposomes in the conju-
gation process, during which repeated and prolonged
stirring was applied [41].
To demonstrate the specific cell binding and internal-
ization of LHRHa-Lip, LHRHR positive A2780/DDP
cells were chosen as target cells, while LHRHR negative
SKOV3 cells were applied as negative control, and the
non-targeted liposomes was also prepared and used as
the control. LSCM analysis revealed that the fluores-
cence intensity in A2780/DDP cells plus LHRHa-C6Ls
group was stronger than that in A2780/DDP cells plus
C6Ls and SKOV3 cells plus LHRHa-C6Ls groups, this is
associated with the LHRHR targeting ability of LHRHa,
and indicated that LHRHa conjugation does promote
the entry of the liposomes into the LHRHR overex-
pressed cells by receptor-mediated endocytosis [43].
FCM data further demonstrated that LHRHa-C6Ls re-
sulted in significantly higher cellular uptake by A2780/
DDP cells. All these results further suggested that
LHRHa-Lip could enhance the specific cell binding and
cellular uptake in A2780/DDP cells due to the mediating
of LHRHa, and depending on the LHRHR expression
level on cell surface as well.
BJOE, BJOLs and LHRHa-BJOLs were found to inhibit
A2780/DDP cells proliferation and induce cell apoptosis
in some extent, and the LHRHa-BJOLs exhibited the stron-
gest inhibitory and apoptosis effect, this was consistent
with the results of cellular uptake discussed above. Further-
more, the in vivo study showed that the median survival
time of the animal in LHRHa-BJOLs group was signifi-
cantly longer than that in BJOLs and BJOE groups at com-
parable dose of BJO. This may be a consequence of the
targeted deposit of LHRHa-BJOLs in the tumor tissue. The
mechanisms of this superior ovarian cancer targeting ability
of LHRHa-Lip has not been fully understood yet. We be-
lieve that this mechanisms might be associated with at least
the following contributing factors. First of all, LHRHa acted
as an anchor to actively hold the liposomes specifically to
the tumor site and promote the receptor-mediated endo-
cytosis. Second, the DSPE-PEG2000 anchored to the
surface of LHRHa-Lip are able to avoid rapid uptake by the
RES, thus prolonging the circulation time and resulting in
a higher accumulation of the liposomes in the tumor
vasculature [44]. Third, the optimal particle size of the
LHRHa-Lip plays an important role in the increased accu-
mulation by the EPR effect as discussed above. Forth,
LHRHa-Lip improve the pharmacokinetic profile of BJO
due to the PEGylated materials [45, 46], which ultimately
results in a higher accumulation in tumors. The results
might further indicated that both active and passive tumor
targeting mechanisms were involved in LHRHa-Lip
accumulation within tumor, in which active targeting
was achieved by LHRHa conjugation to liposomes
and passive targeting was attributed to the EPR effect
of liposomes [47].
To further investigate the mechanisms underlying the
enhanced tumor-inhibition activity of LHRHa-BJOLs,
tumor apoptosis was also evaluated by western blot ana-
lysis. Activation of bax and caspase 3, inhibition of bcl-2
Fig. 6 The survival curve of the mice in different treatment groups (n = 5 in each group). The LHRHa-BJOLs group exhibited the longest survival
time which was significantly longer than other three groups (p < 0.05)
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expression, and decline of MMP are crucial findings,
the LHRHa-BJOLs group exhibited significantly more
changes than the other groups both in vitro and in vivo.
We speculated that the following possible mechanisms
might be involved in the enhanced antitumor efficacy of
LHRHa-BJOLs. Firstly, LHRHa modification and smaller
particle size enhanced the accumulation of BJO in tumor
cells which was discussed above, and this is the prerequis-
ite for the BJO to function. Secondly, LHRHa-BJOLs
upregulated bax, an important pro-apoptotic protein in
mitochondrial pathway [48], and downregulated bcl-2,
one member of the anti-apoptotic bcl-2 family proteins
and critical determinants of mitochondrial-dependent
caspase activation [49]. As a result, the mitochondrial-
initiated apoptosis was promoted, and this was also con-
firmed by the reduced MMP of A2780/DDP cells, which
is the result of a mitochondrial leak by opening the
permeability transition pores [44]. Thirdly, LHRHa-BJOLs
upregulated caspase 3, an important promoters of the
death receptor-mediated apoptosis [50, 51], and resulted
in activation of the death receptor pathway. Taken to-
gether, it could be proposed that LHRHa-BJOLs induced
apoptosis in A2780/DDP cells in vitro or in ovarian tumor
tissue in vivo via simultaneous activation of the death
receptor pathway and the mitochondrial pathway.
Therefore, the LHRHa-BJOLs exhibited a promising
ovarian cancer cells targeting capability and enhanced
therapeutic efficiency both in vitro and in vivo experi-
ments. However, this study also has some limitations.
Firstly, BJO is a complex mixture of fatty acids and its
derivatives, and its main activity components are oleic
acid and linoleic acid with content of 63.3 and 21.2 %
[10], whether the anti-tumor effect of BJO in ovarian
cancer was result from the existence of oleic acid or
linoleic acid still needed to be further verified. Secondly,
we fabricated the targeted liposomes via avidin–biotin
interactions, although this method has been demon-
strated successfully in animal models, its clinical feasibil-
ity is challenged by the unwanted immunogenicity. To
overcome this limitation, one possible technical ap-
proach is to design avidin in the less immunogenic
forms, and the other approach is to use other covalent
and non-covalent binding strategies to synthesize tumor
targeting liposomes. Further research and validation ef-
forts are required before these technical advances can be
implemented in a clinical setting. Finally, no complete
recovery was observed for any treated mice in this study,
because we chose to initiate the treatment on the 15th
day after tumor cell inoculation when the tumors were
readily palpable and stop the treatment on the 27th day
after inoculation. In order to further improve the out-
come, we will consider the optimal therapeutic strategies
in the future, such as earlier initiation of the treatment,
increase of dose and prolongation of treatment.
Conclusions
In summary, we have demonstrated successful synthesis
of a new LHRHa modified and BJO-loaded liposomes
(LHRHa-BJOLs), which have a uniformly spherical shape,
appropriate particle size and zeta potential, as well as a
high encapsulation efficiency. Compared to non-targeted
liposomes (BJOLs) and free BJOE, the LHRHa-BJOLs can
significantly enhance the specific intracellular uptake, cell
inhibition and apoptosis in A2780/DDP cells in vitro.
Meanwhile, LHRHa-BJOLs have a significantly stronger
activity of inhibiting tumor growth, inducing tumor apop-
tosis and prolonging survival time in ovarian cancer-
bearing mice model in vivo. LHRHa-BJOLs can provide a
more effective chemotherapy strategy for the LHRHR-
positive ovarian cancer.
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